• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Alnylam Pharmaceuticals, Inc.

    < Previous 1 2 3 4 5 Next >
    Alnylam to Webcast Presentations at Upcoming June Investor Conferences
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam to Webcast Presentations at Upcoming May Investor Conferences
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam to Webcast Presentation at Stifel 2022 CNS Days
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Issues 2021 Corporate Responsibility Report
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Debuts New Documentary, Two of Me: Living with Porphyria, to Help Shorten Time to Diagnosis for Acute Hepatic Porphyria (AHP)
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare Conference
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    Alnylam to Webcast Presentations at Upcoming Investor Conferences
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ALNY
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.